ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.305,57
-0,34%
S&P 500
5.304,72
0,70%
US Dollar vs BRL
5,14072
-0,59%
Bitcoin
68.325,86
-0,27%
Brent Oil
82,035
0,07%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Neoleukin Therapeutics Inc (NLTX)

  7. Neoleukin Therapeutics Inc (NLTX) Notícias

NLTX

Neoleukin Therapeutics (NLTX)

Neoleukin Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NLTX
DataHoraFonteTítuloCódigoCompanhia
10/05/202417:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NLTXNeoleukin Therapeutics Inc
10/05/202408:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NLTXNeoleukin Therapeutics Inc
26/04/202415:34Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NLTXNeoleukin Therapeutics Inc
26/04/202415:33Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:NLTXNeoleukin Therapeutics Inc
26/04/202415:33Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NLTXNeoleukin Therapeutics Inc
18/03/202417:04Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NLTXNeoleukin Therapeutics Inc
14/03/202421:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
07/03/202418:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
20/02/202418:16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NLTXNeoleukin Therapeutics Inc
14/02/202420:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NLTXNeoleukin Therapeutics Inc
14/02/202418:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NLTXNeoleukin Therapeutics Inc
18/01/202420:45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
21/12/202318:05Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:NLTXNeoleukin Therapeutics Inc
14/12/202321:00GlobeNewswire Inc.Neoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitNASDAQ:NLTXNeoleukin Therapeutics Inc
06/12/202318:24Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:NLTXNeoleukin Therapeutics Inc
14/11/202302:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NLTXNeoleukin Therapeutics Inc
08/11/202316:34Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:NLTXNeoleukin Therapeutics Inc
22/09/202309:00GlobeNewswire Inc.Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitNASDAQ:NLTXNeoleukin Therapeutics Inc
18/07/202307:30GlobeNewswire Inc.Neurogene and Neoleukin Announce Definitive Merger AgreementNASDAQ:NLTXNeoleukin Therapeutics Inc
12/06/202317:04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NLTXNeoleukin Therapeutics Inc
08/05/202317:19Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NLTXNeoleukin Therapeutics Inc
27/04/202315:01Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:NLTXNeoleukin Therapeutics Inc
27/04/202313:48Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:NLTXNeoleukin Therapeutics Inc
27/04/202313:44Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:NLTXNeoleukin Therapeutics Inc
14/04/202317:52Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:NLTXNeoleukin Therapeutics Inc
21/03/202307:02Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:NLTXNeoleukin Therapeutics Inc
10/03/202310:20Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NLTXNeoleukin Therapeutics Inc
08/03/202319:00GlobeNewswire Inc.Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership TransitionNASDAQ:NLTXNeoleukin Therapeutics Inc
14/02/202318:40Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NLTXNeoleukin Therapeutics Inc
03/02/202313:56Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:NLTXNeoleukin Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:NLTX

Seu Histórico Recente

BOV
SGPS3
SPRINGS ON
BOV
COGN3
COGNA ON
BOV
HOOT4
HOTEIS OTHON PN
BOV
PSVM11
PORTO SUDESTE
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados